CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
Ranibizumab 0.3 mg +1 moredrug
Likely dose
Ranibizumab 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02363621
NCT02363621Phase 2Completed
CompareCT.gov

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema

Arshad Khanani·interventional·Posted Feb 16, 2015·Updated Apr 26, 2019

In Brief

A Phase 2 clinical trial evaluating Ranibizumab 0.3 mg and Aflibercept 2.0 mg for Diabetic Macular Edema. Completed, enrolled 101 participants across 1 site.

Detailed Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME. The investigators will be evaluating patients (1-7 days) post injections for: 1\. Intraocular inflammation (defined as anterior chamber and/or vitreous cells 2. Pain (as measured on a standardized pain scale).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 16, 2015
Enrollment StartJan 1, 2015
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.4 years ago

Interventions

Ranibizumab 0.3 mgdrug

Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg

Aflibercept 2.0 mgdrug

Patient will receive intravitreal injection of Aflibercept 2.0 mg